Data from two additional trials examining use of erythropoiesis stimulating agents (ESA) in cancer patients also show increased mortality and more rapid tumor progression when the therapies are used in patients with cancer. In November 2007, the results of six earlier studies led to revisions in the labeling of epoetin alfa (Procrit/Ortho-Biotech) and darbepoetin alfa (
